Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

NCT03493568 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

100

Enrollment

OTHER

Sponsor class

Stopped The futility analysis on 24-week results estimated that there was only 2% probability of verifying the study hypothesis of a higher proportion pat. with no residual viremia through 48w in arm E/C/F/TAF

Conditions

HIV-1-infection

Interventions

DRUG: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
DRUG: Dolutegravir 50 mg plus one RTI

Sponsor

IRCCS San Raffaele

Collaborators

[object Object]